LINTONPHARM
1.12.2021 14:02:14 CET | Business Wire | Press release
LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847 ), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
“The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”
A recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control [1] . Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.
Bladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC [2][3] . Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG [3] .
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell--the epithelial cell adhesion molecule (EpCAM)--and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (clinicaltrials.gov: NCT04222114 ).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. For more information, please visit www.lintonpharm.com .
[1]. Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunology, Immunotherapy. http://doi.org/10.1007/s00262-021-02930-7 |
[2]. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/ |
[3]. Kamat AM, Hahn NM, Efstathiou JA, et al. (2016) Bladder cancer. Lancet 2016. 388: 2796-810. http://dx.doi.org/10.1016/S0140-6736(16)30512-8 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005307/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIPPON KINZOKU Accelerates Global Sales of Ultra-Thin Electrical Steel Strips "GT Series" and "ST Series" as "Fine Eco Metal" Environmentally Friendly Products9.7.2026 10:01:00 CEST | Press release
- Delivering the ultimate balance of “Ultra-Thinness” and “Low Core Loss” to drastically reduce high-frequency energy loss - NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Yasushi Shimokawa; TOKYO: 5491) and its subsidiary, NIKKIN DENJI KOGYO CO., LTD. (Headquarters: Kawaguchi, Saitama; President: Akira Nishimura), are launching a strategic sales initiative for their ultra-thin Grain-Oriented (GT Series) and Non-Oriented (ST Series) electrical steel strips under the brand name "Fine Eco Metal". This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709899733/en/ By reducing the thickness of the electrical steel strip, eddy current loss (core loss) can be significantly lowered. Eddy currents are electrical currents generated within the electrical steel strip by alternating magnetic fields; they are a primary factor that increases core loss. "Fine Eco Metal" is a brand name for our proprietary "Eco-Product" se
3E Acquires Yordas Group: Expanding Leadership in Product Compliance by Augmenting 3E’s Global Regulatory Content and Expertise, and Adding REACH Registration Services9.7.2026 10:00:00 CEST | Press release
3E, the leading global provider of expert-led AI compliance solutions for chemical and workplace safety, product stewardship, and sustainable supply chains, today announced its acquisition of Yordas Group, a leading international provider of scientific consulting and regulatory content services across chemical management, product stewardship, sustainability, and regulatory compliance. Headquartered in Lancaster, UK, with operations in Germany, Canada, Türkiye, and Japan, Yordas serves global brands through its Scientific Services, Regulatory Intelligence, Product Compliance, and Hazard Communication offerings. Solidifying 3E’s Global Regulatory Content Leadership and Breadth of Expertise The acquisition extends 3E's regulatory content leadership and joins two organizations that pride themselves on building and aligning the industry’s top talent of advanced regulatory and chemical experts. It further solidifies 3E as the product compliance solution provider with the industry's broadest
ROYC and PwC Sweden Collaborate to Digitalize Private Equity Structuring & Fund Operations9.7.2026 10:00:00 CEST | Press release
ROYC today announces a strategic collaboration with PwC Sweden to accelerate the digitalization of the GP value chain. The partnership brings together PwC Sweden's market-leading expertise in fund formation and structuring with ROYC’s platform capabilities, with the shared aim of compressing time-to-market, eliminating manual friction in early-phase workflows, and improving the client experience across the full fund lifecycle for fund managers operating across any jurisdiction. "Digitalization of fund operations is overdue. We work alongside fund managers on structuring decisions, regulatory requirements, and operational complexity every day, and the inefficiencies in the early phase are real and costly. What excites me about this collaboration is the practical ambition behind it: taking the knowledge we apply manually today and making it available through a platform that GPs can use from day one. Working directly with the ROYC team in Stockholm makes iteration fast, and the applicatio
Hytera Introduces PDC580 Dual-Mode Rugged Radio to Support Seamless Communication Across Critical Operations9.7.2026 09:25:00 CEST | Press release
Hytera, a leading global provider of critical communications technologies and solutions, announced the launch of the PDC580 Dual-Mode Rugged Radio, developed for organizations that continue to rely on PMR while expanding broadband communications across increasingly distributed operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708879078/en/ Built to connect LTE and PMR, the Hytera PDC580 brings dual-mode communication into one compact rugged radio. “The transition from narrowband to broadband is not an overnight replacement,” said Arthur Luo, Product Manager of Hytera Smart Terminal BU. “Many organizations will operate mixed communication environments for years to come. The PDC580 is designed to make that transition seamless, allowing teams to stay connected without changing established operational workflows.” Many frontline operations involve personnel working across different locations, departments, and network
LR Invests Over €2 Million in Quality and Growth9.7.2026 09:00:00 CEST | Press release
Global demand for innovative health products continues to grow, and with it the requirements for quality, supply reliability and production capacity. LR Health & Beauty is therefore strengthening its Ahlen headquarters with an investment of more than €2 million, laying the foundation for further growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709000261/en/ New, state-of-the-art production line in Ahlen, Germany, manufacturing LR 5in1 Beauty Elixir and LR 5in1 Men's Shot. At the heart of the investment is a new, state-of-the-art production line. LR will use it to fully consolidate the manufacturing of its successful 5-in-1 products at its Ahlen headquarters. This includes, among others, the LR 5in1 Beauty Elixir and the LR 5in1 Men’s Shot. At the same time, the new facility creates the conditions for future product innovations in modern nutritional supplement concepts. By bringing the complete production of its 5-in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom